Latozinemab
拉泽奈单抗
Report date: 2026/01/22 20:00:10
Base Information
Drug NameLatozinemab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[15]
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlector IncGlaxosmithkline Plc
China Registration ClassN/A
Develop Information
Active CompaniesDigital Power Lending LLCAlzamend Neuro Inc
Inactive CompaniesGlaxosmithkline PlcAlector Inc
Active IndicationsN/A
Inactive Indications